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’INTRODUCTION
Precisemolecularcontrolofproteinglycosylationwouldadvance
the development of biopharmaceuticals as well as fundamental
studies of glycosylation-dependent biological processes.
1 4 Bio-
logical methods on their own have failed to achieve this long
sought-after goal, as cellular biosynthetic pathways produce glyco-
proteinsasaheterogeneousmixtureofglycoforms.Glycoprotein
structures with optimal bioactivity are diﬃcult to identify from
such complex mixtures and impossible to generate exclusively
usingconventionalcellhosts.Thetoolsofsyntheticbiologyhave
been harnessed to construct heterologous glycan biosynthetic
pathways in simple host cells.
5,6 While these systems have
produced glycoproteins that are globally modiﬁed with a single
glycan type, no recombinant expression system can yet pro-
duce proteins with discrete glycans at individual sites and with
complete homogeneity.
Chemical synthesis is currently the only plausible approach to
achieve homogeneously glycosylated proteins bearing tailored
glycans at speciﬁc sites.
7 10 Several groups have successfully
combined frontier protein ligation techniques with chemical or
enzymatic glycan and glycopeptide synthesis methods to con-
struct glycoproteins that duplicate natural structures.
11 13 The
valor of these eﬀorts should not be underestimated since the
diﬃculties inherent to glycan and protein syntheses amplify each
otherwhenbothbiopolymerscoexistinthesamesynthetictarget.
14,15
A more practical, though less biologically authentic, approach
involves conjugating glycans to recombinant proteins via un-
natural but synthetically tractable linkages.
16 18 Site-speciﬁcity
in the modiﬁcation can be ensured by outﬁtting the protein with
a noncanonical amino acid side chain capable of chemoselective
ligation with an appropriately functionalized glycan.
19 27
We and others have explored the oxime-forming reaction of
aminooxy glycans with peptide-associated aldehydes or ketones
as a means of site-speciﬁc glycosylation.
25,28,29 This chemistry
proceeds in mildly acidic aqueous buﬀers that are compatible
with most proteins and poses little risk of side reactivity with
endogenous protein or glycan functionalities.
30,31 Despite pro-
mising initial work, however, the generality of the approach
remains limited by two challenges: (1) the need for a practical
means of introducing aldehydes or ketones into recombinant
proteins using standard expression systems, and (2) a reliable
route to synthesize higher-order aminooxy glycans.
The recently developed aldehyde tag methodology answers
the ﬁrst challenge, as it enables site-speciﬁc introduction of
aldehyde-bearing formylglycine (fGly) residues into any recom-
binant protein of interest using conventional Escherichia coli
32
or mammalian
33 expression systems. The aldehyde tag is a ﬁve-
residue consensus sequence (CxPxR, where x is variable) that is
recognizedbytheformylglycinegeneratingenzyme(FGE).
34 36
Cotranslationally, FGE oxidizesthe geneticallyencodedcysteine
residue to fGly, thereby providing a uniquely reactive site for
chemicalmodiﬁcation.AlthoughFGEisnativetomostcelltypes,
coexpression of additional FGE alongside a recombinant protein
substrate ensures high Cys-to-fGly conversion yields. Use of the
aldehyde tag method simply requires cloning the consensus
sequence into the protein’s gene at the desired site of modiﬁca-
tion, followed by protein production in FGE-expressing cells.
In addition to its practicality, the aldehyde tag method bene-
ﬁts from the resemblance of the fGly side chain to naturally
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ABSTRACT: Homogeneously glycosylated proteins are important
targets for fundamental research and for biopharmaceutical develop-
ment. The use of unnatural protein glycan linkages bearing struc-
turalsimilaritytotheirnativecounterpartscanacceleratethesynthesis
of glycoengineered proteins. Here we report an approach toward
generatinghomogeneouslyglycosylatedproteinsthatinvolveschemi-
cal attachment of aminooxy glycans to recombinantly produced
proteins via oxime linkages. We employed the recently introduced
aldehyde tag method to obtain a recombinant protein with the
aldehyde-bearing formylglycine residue at a speciﬁcs i t e .C o m p l e x
aminooxy glycans were synthesized using a new route that features
N-pentenoyl hydroxamates as key intermediates that can be readily elaborated chemically and enzymatically. We demonstrated the
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glycosylated amino acid side chains. Most secreted and cell-
surface vertebrate glycoproteins are modiﬁed at Asn residues
with N-glycans or at Ser/Thr residues with O-glycans (Figure 1A).
We envisioned oxime-linked glycoproteins deriving from con-
jugation of the fGly aldehyde with synthetic aminooxy glycans as
illustrated in Figure 1B. Glycan protein linkages comprising
fGly-derived oximes are close structural mimics of N-glycan
linkages and just one atom longer than O-glycan linkages.
To capitalize on the aldehyde tag as a tool for site-speciﬁc
proteinglycosylation,wesoughttoanswerthesecondchallenge—
a practical and general route to synthesize complex aminooxy
glycans. Here we report on the use of glycosyl N-pentenoyl
hydroxamates as intermediates in the synthesis of higher-order
aminooxy glycans. These analogues function well in both chemi-
cal and enzymatic glycosylation reactions, enabling the eﬃcient
and high-yielding production of both simple and elaborated
aminooxy glycans as substrates for protein conjugation. The
new synthetic approach, together with the aldehyde tag technol-
ogy, enabled the generation of recombinant proteins modiﬁed
site-speciﬁcally with homogeneous glycans.
’RESULTS AND DISCUSSION
Evaluation of N-Hydroxypentenamide as a Masked Amino-
oxy Group.In previous work, aminooxy glycosides were synthe-
sized bydisplacementofa glycosyl halidewithN-hydroxysuccin-
imide (NHS) or N-hydroxyphthalimide (NHPht).
29,37,38 Reaction
yields were acceptable using monosaccharide substrates but, in
our hands, fell precipitously with increasing glycan complexity.
Additionally, glycosylations of NHS and NHPht with other do-
nors, such as glycosyl acetimidates and thioglycosides, were
low yielding, even with monosaccharide substrates. In addition
to falling short as glycosyl acceptors, NHS and NHPht were
inadequate aminooxy protecting groups. They were labile to
basic and reductive conditions, which undermined their use
duringcomplex glycan synthesis.Moreover,we envisionedusing
one-pot multienzyme methods
39 to convert simple aminooxy
glycans into more complex structures. However, such reactions
would require protection of the aminooxy group to avoid oxime
formation with the latent aldehydes or ketones associated with
free sugars. The lability of the NHS and NHPht groups under-
mined our efforts to deprotect late-stage glycan intermediates
without loss of the aminooxy protecting group.
Therefore, we sought to identify an alternative aminooxy
protecting group that possessed better chemical stability overall
but was readily removable under mild conditions that are compatible
withfreesugars.Ideally,thenucleophilicityofthemaskedaminooxy
group would be superior to that of the N-hydroxyimides as well,
thusenhancingreactivityasaglycosylacceptor.Afterscreeninga
varietyofoptions,wefoundtheN-pentenoylprotectinggroupto
be an excellent candidate. Originally introduced by Fraser-Reid
andco-workers,
40 42thepentenoylamideisstabletomanyreac-
tionconditionsandisremovedbygentletreatmentwithaqueous
iodine.Despiteitspotentialasasyntheticsubstrate,N-pentenoyl
hydroxamic acid (1, Table 1, also termed N-hydroxypenten-
amide, which we abbreviate NHPent) has seldom been utilized
in synthesis
43 and, to our knowledge, never as a masked
aminooxy group.
To determine the scope of compound 1's reactivity as a
glycosylacceptor,wesubjectedittoglycosylationreactionsusing
donor substrates that included glycosyl bromides and ﬂuorides,
thioglycosides, and glycosyl acetimidates (Table 1). Most sub-
strates gave acceptable yields of NHPent glycoside product.
The highest yields were obtained using glycosyl N-phenyl
triﬂuoroacetimidates,
44 46 as previously observed in the syn-
theses of glycosyl amides
44 and hydroxamates.
47,48 By contrast,
the less stable glycosyl trichloroacetimidates gave low yields in
glycosylation reactions with 1 under similar conditions (data not
shown).
We anticipated that the mild conditions reported for cleavage
of N-pentenoyl amides would be compatible with unprotected
glycans. To conﬁrm that such conditions can cleave N-alkoxy-
pentenamides without harm to free sugars, we performed model
reactions on the test substrate N-pentenoyl aminooxy lactose
(15, prepared from the known disaccharide aminooxy lactose
28
as shown in Scheme S1). Treatment of N-pentenoyl aminooxy
lactose with 3 equiv of I2 in 1:1 tetrahydrofuran (THF)/H2Oa s
reported
41 resulted in iodocyclization of the NHPent group,
but hydrolysis of the iodoimidate intermediate to aﬀord the
free aminooxy disaccharide was sluggish. Fortunately, the use of
nonaqueous solvent mixtures and acid catalysis, as shown
previously,
49,50alleviatedthisproblem.Weidentiﬁedtheoptimal
deprotectionconditionstobe3equivofI2inwetMeCN/MeOH
with0.1%formic acid(FA)atroomtemperature, whichaﬀorded
quantitative deprotection of N-pentenoyl aminooxy lactose in
under 1 h.
Chemical Synthesis of Aminooxy Lewis x. The utility of
NHPent glycosides as substrates for complex aminooxy glycan
synthesis was demonstrated with the construction of the tri-
saccharide Lewisx(Galβ1,4(Fucα1,3)GlcNAc),aleukocyte and
stem cell marker (Scheme 1).
51,52 We began the synthesis with
the coupling of known trichloroacetimidate 16 to thioglycoside
17 to generate the lactosamine precursor 18 following related,
published routes.
53,54 As seen with similarly protected glucosa-
mine derivatives,
53,54 only glycosylation at the more reactive
4-hydroxyl of 17 was observed. The fucose residue was intro-
duced in the form of 19, which was outfitted with a p-methoxy-
benzyl (PMB) ether at the 2-position to enhance cis-glycosylation.
Similar to a previous report,
55 TfOH-catalyzed coupling of 19
with the free C-3 hydroxyl of 18 proceeded smoothly to afford 20.
Figure 1. Natural glycan linkages resemble the linkage produced by
protein glycoengineering via the reaction of aminooxy sugars with the
aldehyde tag. (A) Linkages naturally found in the most abundant
mammalian N- and O-linked glycan structures. (B) The linkage formed
upon the reaction of an aminooxy glycan with the aldehyde of an fGly-
containing protein. The resulting oxime side chain bears high structural
similarity to the natural glycoprotein attachments.16129 dx.doi.org/10.1021/ja206023e |J. Am. Chem. Soc. 2011, 133, 16127–16135
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ThePMBgroupwasremovedwith10%trifluoroaceticacid,thereby
avoiding reductive or oxidative conditions that are incompatible
with the pentenoyl and thioglycoside groups, and the 2-hydroxyl
group of the fucose residue was acetylated to afford 21.
Motivated by the results in Table 1, we converted thioglycoside
21 to the corresponding glycosyl N-phenyl triﬂuoroacetimidate,
Table 1. Reaction of Various Glycosyl Donors with
N-Pentenoyl Hydroxamic Acid 1
aReactions corresponding to entries 1 7 were conducted in CH2Cl2
(unlessspeciﬁed)at0C,andthosecorrespondingtoentries8 13were
performed at  20 C.
bIsolated yields after column chromatography.
cRatio determined by isolated yields or
1H NMR spectroscopy.
Scheme 1. Chemical Synthesis of Aminooxy Lewis x16130 dx.doi.org/10.1021/ja206023e |J. Am. Chem. Soc. 2011, 133, 16127–16135
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22, for coupling with compound 1.
46 The glycosylation reaction
was conducted with 1 equiv of TMSOTf in dichloromethane at
 20 Ct oa ﬀord N-hydroxypentenoyl trisaccharide 23. The
Troc protecting group was removed with Zn in acidic MeCN,
and the amino group was acetylated. Notably, we observed no
reduction of the N O bond during the Zn reduction step, in
sharp contrast to our previous experience with NHPth glyco-
sides.Removal of the TBDPSand acetylgroups of 24proceeded
in high yield and without damage to the N-hydroxypentenamide
as well. Finally, aminooxy Lewis x was obtained by treatment of
25 with I2 in acidic MeCN/MeOH.
Chemoenzymatic Synthesis of Complex Aminooxy Glycans.
Enzymatic elaboration of synthetic core structures is an increas-
inglypopularstrategyforcomplexglycanassembly.
39,56Enzymes
provide tight stereo- and regiochemical control and obviate the
need for intermediate protecting group manipulations and harsh
chemical conditions. The impact of enzymatic glycosylation
methodsismostevidentincaseswherethechemicalcounterpart
is notoriously difficult, such as in the addition of terminal sialic
acidresiduestoacomplexglycan.
57Giventhebiologicalimportance
of sialosides,
58 we sought to construct sialylated aminooxy glycans
as substrates for glycoprotein engineering.
Trisaccharides 29 and 30 (Scheme 3), termed aminooxy 2,6-
and 2,3-sialyllactose, respectively, were chosen as initial targets
with which toevaluate the performance of NHPent glycosides as
substrates for enzymatic sialylation. We used the one-pot, three-
enzyme system introduced by Chen and co-workers
59,60 to append
sialicacidtoN-pentenoylaminooxylactose(15,Scheme2).This
methodology allows for the in situ generation of costly cytidine
50-monophosphate (CMP)-sialic acid from ManNAc, pyru-
vate, and cytidine 50-triphosphate (CTP) by the combined use
of E. coli aldolase and a CMP-sialic acid synthase, NmCSS.
61
In the same pot, bacterial α-2,6-sialyltransferase (Pd2,6ST) or
α-2,3-sialyltransferase (PmST1) transferred sialic acid to 15,
aﬀordingNHPentglycosides27and28,respectively,inexcellent
yields. Notably, free aminooxy glycans would not be viable
substratesforthisprocedure,astheaminooxygroupwouldundergo
side reactions with free reducing sugars as well as pyruvate. Finally,
we employed our previously optimized deprotection conditions to
obtain trisaccharides 29 and 30 (Scheme 3).
A higher level of complexity was embodied in the tetrasaccharide
sialyl Lewis x (Siaα2,3Galβ1,4(Fucα1,3)GlcNAc, abbreviated
SLe
x), a glycan known for its involvement in cancer progression
andleukocytehoming.
62,63Weenvisionedgeneratingaminooxy-
functionalized SLe
x by chemical synthesis of an NHPent-modiﬁed
disaccharide core,followed byenzymaticinstallationofthe terminal
sialic acid and fucose residues. Toward this end, compound 18
was transformed into NHPent lactosamine derivative 33 by
acetylation of its one free hydroxyl group, conversion of the
thioglycoside to the N-phenyl triﬂuoroacetimidate, and glyco-
sylation with compound 1 (Scheme 4). Deprotection and
N-acetylation gave N-acetyllactosamine NHPent glycoside 35
asasubstrateforenzymaticglycosylation. Theα-2,3-sialoside36
was generated enzymatically as described above for compound
28. After puriﬁcation by size exclusion chromatography, the
fucose residue was installed using the one-pot, two-enzyme
system described by Wu and co-workers.
64 Brieﬂy, guanosine
50-diphosphate (GDP)-fucose was generated in situ from adeno-
sine triphosphate (ATP), guanosine 50-triphosphate (GTP),and
fucose by the Bacteroides fragilis fucose kinase phosphorylase
(FKP). Subsequent glycosylation using Helicobacter pylori α-1,3-
fucosyltransferase (Hp1,3FT) generated tetrasaccharide 37. Fi-
nally, deprotection of 37 with I2 in acidic MeCN/MeOH gave
aminooxy SLe
x 38 in 65% isolated yield.
Conjugation of Aminooxy Glycans to Aldehyde-Tagged
Human Growth Hormone. With a route to complex aminooxy
Scheme 2. Enzymatic Sialylation of N-Pentenoyl Aminooxy Lactose
Scheme 3. Deprotection of NHPent on Sialosides16131 dx.doi.org/10.1021/ja206023e |J. Am. Chem. Soc. 2011, 133, 16127–16135
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glycans established, we sought to combine the synthetic sugars
with recombinant aldehyde-tagged proteins as shown schemati-
cally in Figure 2A. As a protein substrate, we used a previously
reported construct of the human growth hormone (hGH) that
contains a C-terminal aldehyde tag as well as an N-terminal His
tag. The native protein is a well-established biotherapeutic
used in the treatment of human developmental diseases among
others.
65,66Site-specificchemicalmodificationofhGHisapotential
route to improving its pharmacokinetic properties.
67,68 Indeed,
an artificially glycosylated hGH variant was recently shown to
have a prolonged serum half-life in mice.
69
We produced aldehyde-tagged hGH with >95% Cys-to-fGly
conversion in E. coli with coexpression of the FGE from
Mycobacterium tuberculosis.
32 The protein was puriﬁed by chro-
matographyonNi-NTAagaroseandthenreactedwithaminooxy
lactose (S1) in 5% aqueous MeCN with 0.02% FA (pH ∼3.8).
The formation of the lactose glycoconjugate was conﬁrmed by
Western blot probing with the galactose-binding lectin, soybean
agglutinin conjugatedtoﬂuorescein isothiocyanate (SBA-FITC)
(Figure 2B). Signiﬁcant SBA reactivity was observed only for
products of aldehyde-tagged protein conjugation. A control
conjugation reaction using an hGH construct in which the Cys
residue required for the aldehyde installation was mutated to Ala
(CfA) produced no SBA-reactive product. This result con-
ﬁrmed the necessity of the Cys-derived fGly residue for site-
speciﬁc chemical glycosylation with aminooxy lactose. Further,
weanalyzedtheoximeconjugatebyelectrosprayionizationmass
spectrometry (ESI-MS) (Figure 2C). Ions corresponding to
glycosylated(hGH+Lac)andunreacted(hGH)aldehyde-tagged
hGH were observed, the relative intensities of which indicated a
reactionyieldof∼81%.Theproteinglycoconjugatewasfoundto
be highly stable when stored at  20 C, and <10% hydrolysis of
the conjugate was observed after 8 days at 4 C (Table S1).
We performed a similar reaction using the more complex
glycan aminooxy SLe
x (38). The formation of the glycosylated
hGH product was conﬁrmed by Western blot probing with a
SLe
x-speciﬁc antibody as well as with the fucose-binding lectin,
Aleuria aurantia lectin (AAL), conjugated to biotin (Figure 2D).
Usingtheaboveconjugationconditions(5%MeCN,0.02%FA),
the yield of glycosylated hGH as determined by ESI-MS was a
modest 20 25%. However, use of a sodium citrate (NaCit)
buﬀer at pH 3.5 improved the conjugation eﬃciency to ∼64%.
Despite the acidity of the reaction buﬀer, we did not detect any
loss of the potentially labile sialic acid and fucose moieties or any
damage to the aldehyde-tagged protein.
’CONCLUSION
In summary, the facile generation of homogeneous glycopro-
teins was made possible by an improved route to aminooxy
glycans featuring glycosyl N-pentenoyl hydroxamate intermedi-
ates, combined with the genetically encoded aldehyde tag. The
versatility of the aldehyde tag with respect to expression system,
protein target, and site of aldehyde placement makes this
approach broadly useful for protein glycoengineering. In princi-
ple, multiple aldehyde tags can be introduced into a single
protein, allowing for the production of multivalent glycoforms,
a work currently in progress.
The method joins a growing toolkit for site-speciﬁc modiﬁca-
tion of proteins with synthetic glycans, which combined could
produce myriad protein glycoforms with discrete glycans at
diﬀerentpositions.Otherchemoselective ligationreactions,such
asazide alkynecycloadditionsanddisulﬁdeexchangereactions,
have proven useful for modifying a single protein with multiple
moieties.
19 Oxime formation is orthogonal to these and other
chemoselective ligation reactions (thiol ene additions, oleﬁn
metathesis, Suzuki couplings, etc.). Exploring the tandem and
parallel use of these reactions for multiplexed protein modiﬁca-
tion is a subject of future interest.
Scheme 4. Chemoenzymatic Synthesis of Aminooxy SLe
x16132 dx.doi.org/10.1021/ja206023e |J. Am. Chem. Soc. 2011, 133, 16127–16135
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’EXPERIMENTAL SECTION
Phenyl (2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl)-
(1f4)-6-O-(tert-butyldiphenylsilyl)-3-O-acetyl-2-deoxy-2-(2,
2,2-trichloroethoxy)carbonylamino-1-thio-β-D-glucopyrano-
side (31). A solution of disaccharide 18 (400 mg, 0.32 mmol) in
pyridine/Ac2O (2:1, v:v; 4.5 mL) was stirred for 3 h at room tempera-
ture under N2. Upon completion, the reaction was concentrated and
coevaporated with toluene to remove excess Ac2O and AcOH. The
crude residue was purified by silica flash chromatography (Hex/EtOAc
gradient) to obtain fully protected disaccharide 31 as a white powder
(400mg,97%):
1HNMR(500MHz,CDCl3)δ8.18(d,J=7.4Hz,2H),
8.07 (d, J = 7.4 Hz, 2H), 7.93 7.79 (m, 6H), 7.68 7.49 (m, 12H),
7.47 7.34 (m, 5H), 7.33 7.19 (m, 5H), 7.09 (t, J = 7.5 Hz, 2H), 7.03
(t,J=7.3Hz,1H),6.85(t,J=7.7Hz,2H),6.69(d,J=9.0Hz,1H),6.02
(d,J=2.9Hz,1H),5.81(dd,J=10.1,8.2Hz,1H),5.58(dd,J=10.4,3.1
Hz, 1H), 5.50 (t, J = 9.8 Hz, 1H), 5.27 (d, J = 8.0 Hz, 1H), 5.11 (d, J =
10.4 Hz, 1H), 4.90 (q, J = 12.1 Hz, 2H), 4.74 (dd, J = 11.2, 4.6 Hz, 1H),
4.55 4.39 (m,2H),4.30 4.23 (m,1H),4.09 (q,J=10.2 Hz,1H),3.95
(d, J = 11.2 Hz, 1H), 3.77 (d, J = 11.0 Hz, 1H), 3.40 (d, J = 9.7 Hz, 1H),
2.24 (s, 3H), 1.09 (s, 9H);
13C NMR (126 MHz, CDCl3) δ 171.54,
166.00, 165.56, 165.32, 164.45, 154.59, 136.05, 135.67, 135.29, 133.70,
133.52, 133.33, 133.17, 132.91, 131.69, 130.86, 130.25, 129.84, 129.77,
129.74, 129.51, 129.13, 128.77, 128.69, 128.41, 128.29, 128.22, 128.16,
127.78, 126.74, 100.10, 95.78, 85.76, 78.61, 77.41, 74.52, 74.18, 73.61,
72.02, 71.43, 69.90, 68.22, 61.95, 60.96, 54.87, 26.76, 21.24, 19.35;
HRMS (ESI) calcd for C67H65NO16Cl3SSi [M+H]
+ m/z = 1304.2853,
found 1304.2883.
N-Hydroxypent-4-enamide (2,3,4,6-Tetra-O-benzoyl-β-D-
galactopyranosyl)-(1f4)-6-O-(tert-butyldiphenylsilyl)-3-O-
acetyl-2-deoxy-2-(2,2,2-trichloroethoxy)carbonylamino-β-
D-glucopyranoside (33). Thioglycoside 31 (290 mg, 0.22 mmol) was
dissolved in acetone/CH2Cl2/H2O (15:1:1, v:v; 6 mL), and N-iodosuccin-
imide(NIS)(75mg,0.33mmol) wasaddedwhilestirringatroomtemperature.
The reaction was monitored by thin-layer chromatography (TLC) (2:1,
Hex/EtOAc), and N-bromosuccinimide was added in 2 equiv portions
until the reaction was complete. Upon full hydrolysis, the resulting
hemiacetal was diluted in CH2Cl2 and washed sequentially with
Na2S2O3 solution, NaHCO3 solution, and brine. The organic layer
was dried over Na2SO4 and concentrated under reduced pressure. The
resultingresiduewasdissolvedinCH2Cl2(3mL)andCs2CO3(150mg,
0.44 mmol) was added, followed by N-phenyl trifluoroacetimidoyl
chloride(72μL,0.44mmol)dropwise.Thereactionmixturewasstirred
for 12 h at room temperature under N2, after which it was diluted with
CH2Cl2, filtered, and concentrated under vacuum. The crude residue
was purified by silica chromatography to give the trifluoroacetimidate
32 as a yellow oil (267 mg, 87%):
1H NMR (500 MHz, CDCl3) δ
8.16 8.03 (m, 4H), 7.87 7.68 (m, 7H), 7.68 7.31 (m, 14H), 7.19
(dddd, J = 28.0, 16.4, 10.1, 3.9 Hz, 7H), 6.98 (dt, J = 30.6, 15.6 Hz, 1H),
6.71(dd,J=23.5,7.7Hz,1H),6.00 5.92(m,1H),5.83 5.73(m,1H),
5.60 5.40 (m, 1H), 5.33 (t, J =9.9 Hz, 1H), 5.25 (dd, J =22.4, 14.4 Hz,
1H), 5.18 (dt, J = 19.0, 9.4 Hz, 1H), 4.76 (dt, J = 28.6, 14.3 Hz, 1H),
4.63 4.51 (m, 2H), 4.47 4.35 (m, 1H), 4.29 4.17 (m, 1H), 4.13 (dt,
J = 13.7, 7.1 Hz, 1H), 4.05 3.69 (m, 2H), 3.58 3.26 (m, 1H),
2.20 1.92(m,3H),1.16 1.02(m,9H);
13CNMR(126MHz,CDCl3)
δ173.12,166.12,165.51,165.50,164.72,154.46,136.03,135.47,133.88,
133.84, 133.62, 133.45, 133.35, 130.54, 130.02, 129.92, 129.88, 129.70,
129.58, 129.17, 129.03, 128.87, 128.73, 128.55, 128.44, 128.36, 127.96,
100.52, 95.48, 74.75, 73.37, 73.24, 72.20, 71.66, 69.90, 68.23, 62.14,
60.53, 54.23, 26.90, 20.97, 19.50. A mixture of trifluoroacetimidate 32
(257mg,0.186mmol)andN-pentenoylhydroxamicacid1(32mg,0.28
mmol) was dried by coevaporation with anhydrous toluene and left
underhighvacuum.Tothedriedmixturewasadded3ÅMSwithstirring
in CH2Cl2 (4 mL) for 1 h at room temperature under N2. The solution
was cooled to  20 C, and TMSOTf (34 μL, 0.19 mmol) was added
dropwise. The reaction was allowed to warm to room temperature over
1.5 h and was quenched with triethylamine, filtered, and concentrated
under vacuum. The resulting residue was purified by silica flash
chromatography (toluene/acetone gradient) to obtain N-hydroxypen-
tenoyldisaccharide33asawhitesolid(160mg,66%):
1HNMR(500MHz,
Figure2. Generationofsite-speciﬁcallyglycosylatedhGH.(A)Aldehyde-taggedhGHwasreactedwithsyntheticaminooxyglycanstoyieldtheoxime-
glycosylated conjugates. (B) Western blot of aldehyde-tagged hGH (lane 1) or the CfA mutant (lane 2) after reaction with aminooxy lactose S1 (5%
MeCN, 0.02% FA, 0.26 mg/mL aldehyde-tagged hGH, 1 mM S1,1 6h ,3 7C). The blot was probed with SBA-FITC (top), and total protein was
detected by Ponceau stain (bottom). (C) ESI-MS spectrum of the crude reaction mixture showing ions in the 20+ and 21+ charge states. Ions
corresponding to aldehyde-tagged hGH (hGH) and glycosylated hGH (hGH+Lac) are shown with arrows. (D) Western blot of aldehyde-tagged hGH
(lane1)ortheCfAmutant(lane2)afterreactionwithaminooxySLe
x38(50mMNaCit,pH3.5,0.26mg/mLaldehyde-taggedhGH,1mM38,16h,
37C).Theblotwasprobedwithananti-SLexantibodyKM93followedbyahorseradishperoxidase (HRP)-conjugatedsecondaryantibody(top),and
then stripped and reprobed with AAL-biotin followed by a FITC-conjugated antibiotin antibody (middle). Total protein loading was conﬁrmed by
Ponceaustaining(bottom).(E)ESI-MSspectrumoftheSLe
xcrudereactionmixtureshowingionsinthe20+and21+chargestates.Ionscorresponding
to aldehyde-tagged hGH (hGH) and glycosylated hGH (hGH+SLe
x) are shown with arrows.16133 dx.doi.org/10.1021/ja206023e |J. Am. Chem. Soc. 2011, 133, 16127–16135
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CDCl3) δ 8.45 (s, 1H), 8.15 8.02 (m, 4H), 7.83 7.74 (m, 4H),
7.74 7.65 (m, 4H), 7.60 (dt, J = 21.6, 6.4 Hz, 2H), 7.54 7.36 (m,
12H),7.25 7.20(m,2H),7.20 7.16(m,2H),5.95(d,J=3.2Hz,1H),
5.82 5.69(m,2H),5.69 5.61(m,1H),5.48(dd,J=10.3,3.2Hz,1H),
5.20 (t, J = 9.3 Hz, 1H), 5.12 (d, J = 8.0 Hz, 1H), 5.01 (d, J = 16.5 Hz,
1H), 4.96 (d, J = 10.3 Hz, 1H), 4.86 (d, J = 12.0 Hz, 1H), 4.68 (t, J = 9.1
Hz,2H),4.53(d,J=6.4Hz,2H),4.34(t,J=9.3Hz,1H),4.17(t,J=6.0
Hz, 1H), 3.94 3.77 (m, 3H), 3.27 (d, J = 9.4 Hz, 1H), 2.35 2.15 (m,
4H),2.12(s,3H),1.08(s,9H);
13CNMR(126MHz,CDCl3)δ171.32,
170.85, 166.00, 165.51, 165.43, 165.21, 164.72, 136.58, 136.08, 136.06,
136.02, 135.95, 135.48, 135.44, 133.81, 133.51, 133.46, 133.43, 133.29,
130.54, 130.15, 130.09, 130.04, 129.98, 129.93, 129.85, 129.65, 129.49,
128.91, 128.83, 128.68, 128.64, 128.60, 128.45, 128.41, 128.32, 128.11,
127.85, 127.77, 115.81, 100.22, 95.41, 75.63, 74.87, 74.71, 73.14, 71.91,
71.50,69.83,68.08,62.01,60.64,54.00,53.53,28.98,26.86,20.95,19.42;
HRMS (ESI) calcd for C66H67N2O18Cl3Si [M+H]
+ m/z = 1309.3296,
found 1309.3315.
N-Hydroxypent-4-enamide (2,3,4,6-Tetra-O-benzoyl-β-D-
galactopyranosyl)-(1f4)-6-O-(tert-butyldiphenylsilyl)-3-O-
acetyl-2-deoxy-2-acetamido-β-D-glucopyranoside (34). To a
solution of N-hydroxypentenoyl disaccharide 33 (140 mg, 0.11 mmol)
in 10% FA/MeCN (3 mL) was added activated Zn (500 mg), and the
mixture was stirred for 3 h. The suspension was filtered to remove
catalyst, concentrated under vacuum, and coevaporated with toluene to
remove excess FA. The crude free amine was dissolved in anhydrous
MeOH (3 mL), followed by dropwise addition of Ac2O (55 μL, 0.54
mmol) and N,N-diisopropylethylamine (DIPEA) (22 μL, 0.13 mmol) at
0 Cu n d e rN 2. After 1.5 h, the reaction was allowed to warm to room
temperature, diluted with MeOH, and concentrated under vacuum. The
resultingresiduewaspurified by silicaflashchromatography (toluene/acetone
gradient) togivetheN-acetylateddisaccharide 34asawhitesolid(97mg,
77%):
1HNMR(500MHz,CDCl3)δ9.32(s,1H),8.13 8.03(m,4H),
7.82 7.73 (m, 4H), 7.72 7.67 (m, 2H), 7.66 7.54 (m, 6H),
7.52 7.45 (m, 8H), 7.41 7.37 (m, 2H), 7.23 (t, J = 7.8 Hz, 3H),
7.17(t,J=7.8Hz,2H),6.19(d,J=8.4Hz,1H),5.96(d,J=3.1Hz,1H),
5.82 5.69 (m, 2H), 5.48 (dd, J = 10.4, 3.4 Hz, 1H), 5.11 (dd, J = 17.2,
7.9 Hz, 2H), 5.00 (dd, J = 17.2, 1.3 Hz, 1H), 4.94 (d, J = 10.2 Hz, 1H),
4.60 (d, J = 8.5 Hz, 1H), 4.58 4.47 (m, 2H), 4.36 (t, J = 9.1 Hz, 1H),
4.20 4.10 (m, 2H), 3.88 (q, J = 11.2 Hz, 2H), 3.26 (d, J = 9.4 Hz, 1H),
2.38 2.15 (m, 4H), 2.14 (s, 3H), 2.02 (s, 3H), 1.06 (s, 9H);
13CN M R
(126MHz,CDCl3)δ172.53,171.81,170.88,166.04,165.46,164.88,137.93,
136.75, 136.06, 135.74, 135.43, 133.81, 133.56, 133.43, 133.40, 131.23,
130.58, 130.15, 129.94, 129.89, 129.85, 129.54, 129.11, 128.98, 128.82,
128.73, 128.65, 128.52, 128.41, 128.30, 128.26, 127.78, 125.38,
115.62, 102.03, 100.27, 75.89, 72.99, 72.35, 71.86, 71.59, 69.83, 68.17,
62.07, 60.56, 52.23, 32.87, 29.04, 26.82, 23.35, 21.53, 21.03, 19.41;
HRMS (ESI) calcd for C65H68N2O17Si [M+H]
+ m/z = 1177.4360,
found 1177.4396.
N-Hydroxypent-4-enamide (β-D-Galactopyranosyl)-(1f4)-2-
deoxy-2-acetamido-β-D-glucopyranoside (35). A solution of
N-hydroxypentenoyl disaccharide 34 (94 mg, 0.080 mmol) in THF
(4 mL) was cooled to 0 C, and tetrabutylammonium fluoride (1 M in
THF, 160 μL) was added dropwise under N2. The mixture was allowed
to warm to room temperature and stirred for 18 h, after which it was
diluted with EtOAc and concentrated under reduced pressure. The
resulting residue was dissolved in MeOH (4 mL), and NaOMe (25% in
MeOH, 40 μL) was added dropwise with stirring at room temperature.
After 8 h, the reaction was neutralized with Dowex 50W-X8 (H
+) and
filtered to remove resin. The crude product was concentrated under
vacuum and purified by silica column chromatography (10 25%
MeOH/CH2Cl2). The purified residue was filtered to remove trace
silica and lyophilized to yield the deprotected N-hydroxypentenoyl
LacNAc 35 as a white powder (32 mg, 84%):
1H NMR (500 MHz,
D2O) δ 5.80 (ddt, J = 12.8, 10.3, 6.5 Hz, 1H), 5.10 4.98 (m, 2H),
4.75 (d, J = 8.8 Hz, 1H), 4.44 (d, J = 7.8 Hz, 1H), 3.98 3.92 (m, 1H),
3.92 3.80(m,3H),3.77 3.66(m,5H),3.63(dd,J=10.0,3.4Hz,1H),
3.61 3.54(m,1H),3.50(dd,J=9.8,7.9Hz,1H),2.32(dd,J=13.1,6.5
Hz, 2H), 2.28 2.21 (m, 2H), 2.02 (s, 3H);
13C NMR (126 MHz,
CDCl3) δ 174.72, 172.85, 136.46, 115.89, 103.79, 102.82, 77.78, 75.33,
75.06,72.45,72.22,70.91,68.51,61.00,59.77,52.90,31.72,28.81,22.18;
HRMS (ESI) calcd for C19H32N2O12 [M+H]
+ m/z = 481.2028, found
481.2036.
N-Hydroxypent-4-enamide (5-Acetamido-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2f3)-β-
D-galactopyranosyl-(1f4)-2-deoxy-2-acetamido-β-D-gluco-
pyranoside (36). To N-pentenoyl aminooxy LacNAc 35 (21 mg,
0.044 mmol) were added N-acetylmannosamine (15 mg, 0.066 mmol),
sodium pyruvate (24 mg, 0.22 mmol), and CTP3Na (37 mg, 0.066
mmol),andtheyweredissolvedinH2O(3mL).Aconcentratedstockof
Tris-HClbufferpH8.5withMgCl2wasaddedtoafinalconcentrationof
100 mM Tris, 20 mM MgCl2. Recombinant E. coli K12 sialic acid
aldolase (4 U), Neusserua meningitidis CMP-sialic acid synthetase (4 U),
and Pasteurella multocida α-2,3-sialyltransferase (2 U) were added,
followed by H2O, to bring the volume to 4 mL. The reaction mixture
wasincubatedat37Cfor2h,followedbyshakingatroomtemperature
for 14 h. The reaction was monitored by TLC (4:2:1 EtOAc/MeOH/
H2O), and upon completion, calf alkaline phosphatase was added to
remove remaining nucleotide phosphate. After further incubation at
37 C for 2 h, the reaction mixture was quenched with cold MeOH
(4 mL) and incubated on ice for 20 min. The mixture was centrifuged,
precipitates were removed, and the solution concentrated under
vacuum. The resulting residue was passed through a BioGel P-2 size
exclusion column and eluted with ddH2O to obtain 36 (28.9 mg, 86%)
asawhite,fluffypowderafterlyophilization:
1HNMR(600MHz,D2O)
δ 5.80 (ddt, J = 16.9, 10.3, 6.6 Hz, 1H), 5.09 4.99 (m, 2H), 4.74 (d, J =
8.8Hz,1H),4.52(d,J=7.9Hz,1H),4.08(dd,J=9.9,3.1Hz,1H),3.96
(app d, J = 10.7 Hz, 1H), 3.92 (d, J = 3.0 Hz, 1H), 3.88 3.79 (m, 5H),
3.76 3.70 (m, 3H), 3.69 3.64 (m, 3H), 3.62 3.52 (m, 5H), 2.73 (dd,
J = 12.4, 4.6 Hz, 1H), 2.31 (dd, J = 13.5, 6.7 Hz, 2H), 2.24 (app t, J =7.0
Hz, 2H), 2.02 (s,3H), 2.00 (s, 3H),1.77 (t, J=12.1 Hz, 1H);
13C NMR
(151 MHz, D2O) δ 175.00, 174.73, 173.83, 172.51, 136.54, 115.87,
103.81, 102.54, 99.79, 77.73, 75.46, 75.16, 75.08, 72.87, 72.20, 71.74,
69.34,68.31,68.08,67.45,62.57,61.01,59.81,59.42,52.91,51.67,39.62,
31.73, 28.81, 22.19, 22.01; HRMS (ESI) calcd for C30H49N3O20
[M H]
  m/z = 770.2837, found 770.2812.
N-Hydroxypent-4-enamide (5-Acetamido-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2f3)-β-
D-galactopyranosyl-(1f4)[(1f3)-α-L-fucopyranosyl]-2-deoxy-
2-acetamido-β-D-glucopyranoside (37). To a 5 mL solution of
100 mM Tris buffer (pH 7.5) containing 5 mM L-fucose (0.025 mmol),
5 mM MgSO4 (0.025 mmol), 10 mM GTP3Na (0.05 mmol), and
10 mM ATP3Na (0.05 mmol) were added Saccharomyces cerevisiae
inorganic pyrophosphatase (40 U) and B. fragilis FKP (4 U). The
mixture was incubated at 37 C for 2 h to preform GDP-fucose and
monitored by TLC (2:1:1 iPrOH/AcOH/H2O). To this was added
N-pentenoyl aminooxy sialoside 36 (5 mg, 0.07 mmol) and H. pylori
α-1,3 fucosyltransferase (1 U), followed by incubation at room tem-
perature for 16 h. The reaction was monitored by TLC (4:2:1 EtOAc/
MeOH/H2O), and upon completion, calf alkaline phosphatase was
added to remove remaining nucleotide phosphate. After further incuba-
tion at 37 C for 2 h, the reaction mixture was quenched with cold
MeOH (5 mL) and incubated on ice for 20 min. The mixture was
centrifuged, precipitates were removed, and the solution was concen-
tratedundervacuum.TheresultingresiduewaspassedthroughaBioGel
P-2 size exclusion column and eluted with ddH2O to obtain 37 (4.6 mg,
78%) as awhite, fluffypowder after lyophilization:
1HNMR (600MHz,
D2O) δ 5.88 5.77 (m, 1H), 5.06 (dd, J = 26.6, 14.1 Hz, 3H), 4.81 (app
s, 1H), 4.51 (d, J = 7.7 Hz, 1H), 4.12 4.01 (m, 2H), 3.97 (dd, J = 20.8,16134 dx.doi.org/10.1021/ja206023e |J. Am. Chem. Soc. 2011, 133, 16127–16135
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10.7 Hz, 2H),3.92 3.82 (m, 7H),3.75 (d, J=12.5 Hz,1H), 3.70 3.55
(m, 10H), 3.51 (t, J = 8.7 Hz, 1H), 2.79 2.70 (m, 1H), 2.37 2.30 (m,
2H), 2.30 2.22 (m, 2H), 2.02 (d, J = 4.1 Hz, 6H), 1.78 (t, J = 12.2 Hz,
1H), 1.15 (d, J = 6.1 Hz, 3H);
13C NMR (151 MHz, D2O) δ 175.04,
174.51, 173.79, 172.53, 136.55, 115.88, 103.70, 101.62, 99.64, 98.61,
75.65,75.57,74.91,74.58,72.92,71.89,71.83,69.24,69.19,68.26,68.12,
67.70,67.30,66.70,62.62,61.44,59.52,59.33,53.56,51.70,39.78,31.73,
28.80, 22.29, 22.03, 15.25; HRMS (ESI) calcd for C36H59N3O24
[M H]
  m/z = 916.3416, found 916.3394.
Aminooxy (5-Acetamido-3,5-dideoxy-D-glycero-α-D-galacto-
2-nonulopyranosylonic acid)-(2f3)-β-D-galactopyranosyl-
(1f4)[(1f3)-α-L-fucopyranosyl]-2-deoxy-2-acetamido-β-D-
glucopyranoside (38). A solution of N-hydroxypentenoyl SLe
x 37
(4.2 mg, 0.0046 mmol) in MeCN/MeOH/FA (3:1:0.001, v:v; 1.6 mL)
was stirred at room temperature with dropwise addition of I2 (0.014
mmol, 0.5 M solution in THF). The mixture was heated to 35 C and
stirred for 2 h, after which the reaction was quenched with the addition
of aqueous NH4HCO3 (500 mM) and Na2S2O3 (50 mM) until the
disappearance of color. The solvent was removed under reduced
pressure, and the remaining residue was purified by silica flash chroma-
tography (4:2:1 EtOAc/MeOH/H2O). The desired fractions were
pooled and concentrated under vacuum. The purified product was
dissolved in ddH2O and lyophilized to give the free aminooxy SLe
x 38
(2.5mg, 65%)asawhite powder:
1HNMR(600MHz, D2O)δ 5.11(d,
J = 4.0 Hz, 1H), 4.72 (d, J = 8.7 Hz, 1H), 4.52 (d, J = 7.8 Hz, 1H), 4.09
(dd, J = 9.9, 3.0 Hz, 1H), 4.04 (dd, J = 14.8, 4.7 Hz, 1H), 3.98 (dd, J =
18.7,9.6Hz,2H),3.94 3.92(m,1H),3.92 3.87(m,5H),3.86(dd,J=
13.6, 6.3 Hz, 2H), 3.78 (app d, J = 2.8 Hz, 1H), 3.70 3.63 (m, 8H),
3.61 3.56(m,3H),3.55 3.51(m,1H),2.76(dd,J=12.4,4.6Hz,1H),
2.03 (s, 6H), 1.80 (t, J = 12.2 Hz, 1H), 1.17 (d, J = 6.6 Hz, 3H);
13C
NMR(151MHz,D2O)δ175.06,174.51,173.78,103.04,101.65,99.95,
99.66,98.61,75.68,75.37,74.92,74.71,73.18,72.95,71.90,71.84,69.27,
69.20,68.27,68.15,67.72,67.32,66.72,62.65,61.46,59.69,53.94,51.72,
43.35, 39.79, 22.18, 22.05, 15.27; HRMS (ESI) calcd for C31H52N3O23
[M H]
  m/z = 834.2994, found 834.2997.
General Procedure for Coupling Aminooxy Sugars to
Aldehyde-Tagged Protein. Toa solution of 5% MeCN, 0.02% FA,
or 50 mM NaCit, pH 3.5, was added 0.26 mg/mL aldehyde-tagged
proteinand1mMaminooxysugar.Thereactionwasincubatedat37C
for 18 h, at which point the reaction was quenched with 4  protein
loading dye and resolved by SDS-PAGE. The protein was transferred to
n i t r o c e l l u l o s ea n dp r o b e dw i t ha n t i - s i a l y lL e w i sxI g M( K M 9 3 ,C h e m i c o n ,
1:500 dilution) followed by anti-mouse IgM-HRP (Southern Biotech,
1:10000) in 5% dry milk in phosphate-buffered saline/0.1% Tween
(PBST). The presence of galactose was probed with SBA-FITC (EY,
1:1000 dilution) in 3% bovine serum albumin (BSA)/PBST. For fucose
analysis, the nitrocellulose was probed with AAL-biotin (EY Labs,
1:1000 dilution) followed by rabbit anti-biotin FITC (Abcam, 1:1000)
in 3% BSA/PBST. Membranes were developed by chemiluminescence
using the SuperSignal West Pico kit (Thermo) or scanned for fluores-
cence by a Typhoon 9410 imaging system (Amersham). For mass
spectrometry analysis, the protein was reacted in 5% MeCN, 0.02% FA,
or NaCit at1 mg/mLwith2 mMaminooxy sugarfor18 h at37C.The
reaction was quenchedwith1M TrisbufferpH8,andthe crude protein
was purified by reversed-phase high-performance liquid chromatogra-
phy (PLRP-S, Polymer Laboratories) with elution in aqueous MeCN.
The multicharged peaks of the full length protein were obtained by
ESI-MS (Bruker/Agilent Esquire) and identified by mass spectrometry
analysis software. For stability analysis, the purified glycoconjugate was
diluted to 10 μM in PBS at pH 7.2 and stored at  20 or 4 C. Aliquots
were taken at various time points and analyzed by matrix-assisted laser
desorption/ionization mass spectrometry to determine the remaining
glycoconjugate.
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